Interview with Hoon Han, President, Histostem
After spending a large part of your career as a university professor, what drove you to create your own company, Histostem, in 2000? In 1993, I actually established a bone…
Address: Seongnam jungwongu beltway 210 (sangdaewondong) 101
Tel: (031)-732-1555
Web: http://www.seoulcord.co.kr/index1.asp
Histostem is a stem cell provider, specializing in the MLPCs (Multi-Lineage Progenitor Cells) research, the treatment of disease and injury, and the banking of stem cells. Stem cells are the body’s “master” cells because they give rise to all other tissues, organs, and systems in the body. The stemcells’ ability to differentiate, or change, into other types of cells in the body, is a fairly new discovery that holds tremendous promise for treating and curing some of the most common diseases such as heart diseases, cancers, stroke, paralysis, liver cirrhosis, Buerger’s and Alzheimer’s diseases. What’s more, this treatment is not years away. Histostem is already using hematopoietic stemcells taken from UCB to treat blood diseases such as various kinds of leukemia, multiple sclerosis, amyotrophic lateral sclerosis, etc. Histostem also succeeded in extracting non-hematopoietic multipotent stem cells from UCB in their most pure state and perfected in multiplying and cultivating those stemcells. Histostem is the world’s first runner in applying our stem cell therapy to human patients, and currently using our stem cells to treat with great success such illnesses as Buerger’s disease, Type II diabetes, liver cirrhosis, paralysis after spinal cord injury, osteoporosis, chronic renal failure, and Alzheimer’s disease, to name a few. Finally, in order to achieve the most effective donor matching of cord blood to patient, our research technicians are busy typing the human leukocyte antigens (HLA) in our biogenetics laboratory.
Stem cell provider, specializing in the MLPCs (Multi-Lineage Progenitor Cells) research, the treatment of disease and injury, and the banking of stem cells.
After spending a large part of your career as a university professor, what drove you to create your own company, Histostem, in 2000? In 1993, I actually established a bone…
The CEO of Mega Medical, a Korean medical equipment manufacturer specialized in the ENT area, discusses his firm’s recent expansion into the anti-obesity segment, their strategy for building a global…
SillaJen’s CEO shares his passion for his companies oncolytic vaccinia virus, and its potential to revolutionize the treatment of solid tumor cancers, even arguing that it may eventually constitute ‘a…
Albert Liou discusses the success of the government’s investment in clinical trial infrastructure, which has triggered the rapid growth and advancement of the Korean clinical trial market and spurred innovation…
The chairman of contract manufacturer Korea Pharma discusses the Korean CMO market and incremental innovation. Where did your idea for starting Korea Pharma come from? I am a pharmacist…
Tom Roberts came to UCB Korea following a position at the company’s Japanese affiliate in late 2011. He describes the market conditions for UCB’s specialty products and emphasizes the importance…
The CEO of Yungjin, a leading Korean pharma company, talks about the revitalization of the company he has overseen since being appointed in 2010. To begin, could you please…
Chung Seung, Minister of Food and Drug Safety, discusses the latest improvements to Korea’s regulatory system and highlights vaccines, biosimilars and stem cell research as key components of the country’s…
The head of the government agency charged with attracting and promoting FDI in Korea discusses how the country has ideally positioned itself between China and western markets through a series…
Janssen’s managing director in Korea discusses the groups long and significant commitment to R&D in the country, as well as some of the challenges that one of the most innovative…
The founder of MEDIPOST, the producer of the only approved allogenic stem cell product in the world, disucsses their development goals for the coming years and the potential for regenerative…
Christopher Ko was appointed as the Chief Executive Officer of Samsung Bioepis in 2012, then newly founded Korean pharmaceutical company with expertise in biosimilars. In this interview, he discusses the…
After a lengthy career at Novartis, Angie Kim recently started working at BMS Korea to develop the affiliate. She discusses diversifying the company’s portfolio and their footprint in Korea as…
See our Cookie Privacy Policy Here
